18,500 Shares in Novo Nordisk A/S (NYSE:NVO) Bought by Sava Infond d.o.o.

Sava Infond d.o.o. bought a new stake in Novo Nordisk A/S (NYSE:NVO) in the fourth quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund bought 18,500 shares of the company’s stock, valued at approximately $1,591,000.

Several other large investors also recently modified their holdings of the business. GQG Partners LLC grew its position in shares of Novo Nordisk A/S by 74.7% in the 4th quarter. GQG Partners LLC now owns 12,994,533 shares of the company’s stock valued at $1,117,790,000 after purchasing an additional 5,556,460 shares during the period. Raymond James Financial Inc. bought a new position in Novo Nordisk A/S in the fourth quarter valued at approximately $404,910,000. Sustainable Growth Advisers LP boosted its holdings in shares of Novo Nordisk A/S by 23.6% in the fourth quarter. Sustainable Growth Advisers LP now owns 5,340,803 shares of the company’s stock valued at $459,416,000 after buying an additional 1,021,498 shares during the period. Amundi increased its position in shares of Novo Nordisk A/S by 26.4% during the fourth quarter. Amundi now owns 3,311,456 shares of the company’s stock worth $283,615,000 after acquiring an additional 692,567 shares in the last quarter. Finally, Parnassus Investments LLC acquired a new stake in shares of Novo Nordisk A/S during the fourth quarter worth $51,072,000. 11.54% of the stock is currently owned by institutional investors.

Novo Nordisk A/S Price Performance

Shares of NYSE NVO opened at $71.74 on Thursday. Novo Nordisk A/S has a twelve month low of $70.09 and a twelve month high of $148.15. The company has a market cap of $321.94 billion, a PE ratio of 21.81, a price-to-earnings-growth ratio of 0.90 and a beta of 0.42. The business’s 50 day moving average price is $82.78 and its two-hundred day moving average price is $99.75. The company has a quick ratio of 0.55, a current ratio of 0.74 and a debt-to-equity ratio of 0.62.

Novo Nordisk A/S (NYSE:NVO) last posted its quarterly earnings results on Wednesday, February 5th. The company reported $0.91 earnings per share for the quarter, beating analysts’ consensus estimates of $0.88 by $0.03. Novo Nordisk A/S had a return on equity of 84.68% and a net margin of 34.81%. On average, analysts predict that Novo Nordisk A/S will post 3.84 EPS for the current year.

Novo Nordisk A/S Increases Dividend

The business also recently declared a semi-annual dividend, which will be paid on Tuesday, April 8th. Investors of record on Monday, March 31st will be paid a $0.7874 dividend. The ex-dividend date of this dividend is Monday, March 31st. This represents a yield of 1.2%. This is a positive change from Novo Nordisk A/S’s previous semi-annual dividend of $0.51. Novo Nordisk A/S’s dividend payout ratio is 47.72%.

Analyst Upgrades and Downgrades

A number of equities analysts have issued reports on NVO shares. Morgan Stanley initiated coverage on Novo Nordisk A/S in a report on Wednesday, February 12th. They set an “equal weight” rating for the company. BMO Capital Markets decreased their price objective on Novo Nordisk A/S from $156.00 to $105.00 and set an “outperform” rating for the company in a report on Monday, December 23rd. BNP Paribas upgraded Novo Nordisk A/S to a “strong-buy” rating in a research note on Monday, December 2nd. StockNews.com downgraded shares of Novo Nordisk A/S from a “strong-buy” rating to a “buy” rating in a research report on Friday, March 21st. Finally, UBS Group upgraded Novo Nordisk A/S from a “sell” rating to a “buy” rating in a research note on Wednesday, January 8th. Three research analysts have rated the stock with a hold rating, seven have issued a buy rating and one has issued a strong buy rating to the company. According to MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and an average price target of $145.25.

About Novo Nordisk A/S

Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products in Europe, the Middle East, Africa, Mainland China, Hong Kong, Taiwan, North America, and internationally. It operates in two segments, Diabetes and Obesity Care, and Rare Disease.